Compare Elder Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA DIVIS LABORATORIES ELDER PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x -0.2 34.6 - View Chart
P/BV x 0.1 6.6 1.5% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 ELDER PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
DIVIS LABORATORIES
Mar-19
ELDER PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3801,639 23.2%   
Low Rs1881,115 16.9%   
Sales per share (Unadj.) Rs491.2186.3 263.6%  
Earnings per share (Unadj.) Rs-3.251.0 -6.2%  
Cash flow per share (Unadj.) Rs14.457.3 25.1%  
Dividends per share (Unadj.) Rs016.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs376.5261.8 143.8%  
Shares outstanding (eoy) m20.54265.47 7.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.67.4 7.8%   
Avg P/E ratio x-89.327.0 -330.3%  
P/CF ratio (eoy) x19.724.0 82.0%  
Price / Book Value ratio x0.85.3 14.3%  
Dividend payout %031.4 0.0%   
Avg Mkt Cap Rs m5,833365,592 1.6%   
No. of employees `000NA11.8 0.0%   
Total wages/salary Rs m2,1795,423 40.2%   
Avg. sales/employee Rs ThNM4,175.1-  
Avg. wages/employee Rs ThNM457.7-  
Avg. net profit/employee Rs ThNM1,141.8-  
INCOME DATA
Net Sales Rs m10,08949,463 20.4%  
Other income Rs m2571,556 16.5%   
Total revenues Rs m10,34651,019 20.3%   
Gross profit Rs m-79218,718 -4.2%  
Depreciation Rs m3611,689 21.4%   
Interest Rs m2,75635 7,875.1%   
Profit before tax Rs m-3,65318,551 -19.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1255,023 2.5%   
Profit after tax Rs m-6513,527 -0.5%  
Gross profit margin %-7.837.8 -20.7%  
Effective tax rate %-3.427.1 -12.7%   
Net profit margin %-0.627.3 -2.4%  
BALANCE SHEET DATA
Current assets Rs m9,24046,501 19.9%   
Current liabilities Rs m9,9988,468 118.1%   
Net working cap to sales %-7.576.9 -9.8%  
Current ratio x0.95.5 16.8%  
Inventory Days Days46131 35.4%  
Debtors Days Days6086 69.8%  
Net fixed assets Rs m10,12425,797 39.2%   
Share capital Rs m206531 38.7%   
"Free" reserves Rs m5,58268,962 8.1%   
Net worth Rs m7,73469,493 11.1%   
Long term debt Rs m4,8890-   
Total assets Rs m22,88280,383 28.5%  
Interest coverage x-0.3531.0 -0.1%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.6 71.7%   
Return on assets %11.816.9 69.7%  
Return on equity %-0.819.5 -4.3%  
Return on capital %22.326.7 83.4%  
Exports to sales %3.00-   
Imports to sales %0.424.6 1.7%   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m4312,187 0.4%   
Fx inflow Rs m30741,238 0.7%   
Fx outflow Rs m12512,405 1.0%   
Net fx Rs m18128,833 0.6%   
CASH FLOW
From Operations Rs m11,7549,543 123.2%  
From Investments Rs m-561-6,854 8.2%  
From Financial Activity Rs m-6,762-2,459 274.9%  
Net Cashflow Rs m4,432230 1,930.2%  

Share Holding

Indian Promoters % 39.6 52.0 76.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 11.8 63.6%  
FIIs % 16.8 19.0 88.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 17.2 209.9%  
Shareholders   16,479 31,796 51.8%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   AUROBINDO PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  FULFORD INDIA  ALKEM LABORATORIES  

Compare ELDER PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS